research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
Search
for
Sort by
Research
240-270 / 1000+ results
research Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.
research BH07 The socioeconomic burden of alopecia areata
Alopecia areata causes significant financial strain, especially for women and those with severe symptoms.
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
research Guest Editor's Note
The supplement aims to improve care for children with alopecia areata.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
research Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
research P063 Tracking down autoantibodies
A man developed autoimmune symptoms after the Pfizer COVID-19 vaccine, highlighting the need for thorough vaccine safety checks.
research Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production
Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Hypertrichosis of the eyelashes caused by bimatoprost
Bimatoprost can cause excessive eyelash growth.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research <p>A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States</p>
Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
research Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.
research Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.
research Investigation of drug partition property in artificial sebum
The conclusion is that measuring how drugs partition into artificial sebum is important for predicting their delivery into hair and sebaceous follicles, and it provides better information than traditional methods.
research Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
research A method for the determination of minoxidil in hair-regrowth formulations by micellar electrokinetic capillary chromatography
A quick and simple method was created to identify minoxidil in hair-growth products using micellar electrokinetic capillary chromatography.
research The women’s hair growth questionnaire: Development and validation of a patient-reported measure for treatment efficacy in androgenetic alopecia
AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.
research Study of cardiovascular risk factors in patients with androgenetic alopecia: Metabolic syndrome and carotid atheromatosis
People with early-onset hair loss have higher risk of heart issues, so early screening is important.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro
Minoxidil promotes hair growth by penetrating skin, with ethanol-containing formulas working best.
research Comparison of artificial sebum with human and hamster sebum samples
Artificial sebum L closely mimics human sebum for drug delivery research.